Intec Pharma shares dive after Parkinson’s trial failureIntec Pharma’s Parkinson’s gradual release disease drug trial has missed its primary endpoint, causing the biotech’s share price Share XIntec Pharma shares dive after Parkinson’s trial failurehttps://pharmaphorum.com/news/intec-pharma-shares-dive-after-parkinsons-trial-failure/
AI specialist Exscientia forms rare disease JV with RallyBioUK artificial intelligence (AI) drug discovery company Exscientia has formed another R&D alliance, this time in the area Share XAI specialist Exscientia forms rare disease JV with RallyBiohttps://pharmaphorum.com/news/ai-specialist-exscientia-forms-rare-disease-jv-with-rallybio/
Vertex presses go on its cystic fibrosis triple filingVertex has launched the next phase of its plan for the cystic fibrosis market, filing for approval of Share XVertex presses go on its cystic fibrosis triple filinghttps://pharmaphorum.com/news/vertex-presses-go-on-its-cystic-fibrosis-triple-filing/
Biohaven ALS drug blocked by FDA over manufacturing issueBiohaven’s therapy for amyotrophic lateral sclerosis (ALS) has been rejected by the FDA over manufacturing compliance issues for Share XBiohaven ALS drug blocked by FDA over manufacturing issuehttps://pharmaphorum.com/news/biohaven-als-drug-blocked-by-fda-over-manufacturing-issue/
UK’s NHS sitting on patient record gold mine worth billions – reportPatient records held by the UK’s NHS may be worth several billion pounds to commercial organisations, according to Share XUK’s NHS sitting on patient record gold mine worth billions – reporthttps://pharmaphorum.com/news/uks-nhs-sitting-on-patient-record-gold-mine-worth-billions-report/
NICE reviews number crunching methods as advanced technologies hit marketNICE is to review how it develops guidance on drugs, focusing on issues such as modifiers used in Share XNICE reviews number crunching methods as advanced technologies hit markethttps://pharmaphorum.com/news/nice-reviews-number-crunching-methods-as-advanced-technologies-hit-market/
Broad, MilliporeSigma issue call to make access to CRISPR freerGene-editing with CRISPR/Cas9 is promising a revolution in medicine, but battles over intellectual property (IP) have made it Share XBroad, MilliporeSigma issue call to make access to CRISPR freerhttps://pharmaphorum.com/news/broad-milliporesigma-issue-call-to-make-access-to-crispr-freer/
Roche under pressure in US as Amgen/Allergan launch US cancer biosimilarsAmgen and Allergan have launched their cut-price biosimilar competitors to two big-selling cancer drugs from Roche in the Share XRoche under pressure in US as Amgen/Allergan launch US cancer biosimilarshttps://pharmaphorum.com/news/roche-under-pressure-in-us-as-amgen-allergan-launch-us-cancer-biosimilars/
Celgene gets new approval for soon-to-be-shed OtezlaCelgene has picked up a third approval for its anti-inflammatory drug Otezla, although it won’t reap much commercial Share XCelgene gets new approval for soon-to-be-shed Otezlahttps://pharmaphorum.com/news/celgene-gets-new-approval-for-soon-to-be-shed-otezla/
Yale, Mayo and FDA experts aim to rethink heart failure trials with Apple WatchA group of scientists from Yale University and the Mayo Clinic are to use an Apple Watch app Share XYale, Mayo and FDA experts aim to rethink heart failure trials with Apple Watchhttps://pharmaphorum.com/news/yale-mayo-and-fda-experts-aim-to-rethink-heart-failure-trials-with-apple-watch/
Genentech extends small-molecule R&D with three platform dealsRoche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its Share XGenentech extends small-molecule R&D with three platform dealshttps://pharmaphorum.com/news/genentech-extends-small-molecule-rd-with-three-platform-deals/
Boehringer announces IPF deal with Korea’s Bridge TherapeuticsBoehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for Share XBoehringer announces IPF deal with Korea’s Bridge Therapeuticshttps://pharmaphorum.com/news/boehringer-announces-ipf-deal-with-koreas-bridge-therapeutics/
Takeda looking to divest portfolio of older drugs in EuropeTakeda is trying to sell a portfolio of older drugs in western Europe as it seeks to cut Share XTakeda looking to divest portfolio of older drugs in Europehttps://pharmaphorum.com/news/takeda-looking-to-divest-portfolio-of-older-drugs-in-europe/
Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOGenmab has shattered recent records with its Nasdaq listing, raising $506 million to help it advance multiple antibody Share XDenmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOhttps://pharmaphorum.com/news/denmarks-genmab-raises-a-bumper-500m-plus-in-nasdaq-ipo/
Huami set to launch ECG watches outside ChinaHuami is to make its new crop of electrocardiogram smartwatches available to international markets, according to a press Share XHuami set to launch ECG watches outside Chinahttps://pharmaphorum.com/news/huami-set-to-launch-ecg-watches-outside-china/
FDA clears Bayer’s Gadavist as first contrast agent for cardiac MRIBayer’s Gadavist has become the first imaging agent approved in the US to detect blockages in the hearts Share XFDA clears Bayer’s Gadavist as first contrast agent for cardiac MRIhttps://pharmaphorum.com/news/fda-clears-bayers-gadavist-as-first-contrast-agent-for-cardiac-mri/
Gilead’s R&D chief to step down as new CEO O’Day rings the changesGilead’s chief scientific officer, John McHutchison is to leave the company at the beginning of next month during Share XGilead’s R&D chief to step down as new CEO O’Day rings the changeshttps://pharmaphorum.com/news/gileads-rd-chief-to-step-down-as-new-ceo-oday-rings-the-changes/
Novartis ups 2019 guidance after strong Q2Novartis has revised its guidance for 2019 upwards after a strong set of Q2 figures, with its psoriasis Share XNovartis ups 2019 guidance after strong Q2https://pharmaphorum.com/news/novartis-ups-2019-guidance-after-strong-q2/
10 Key Reasons to attend SMi’s 10th Annual Biosimilars Conference Share X10 Key Reasons to attend SMi’s 10th Annual Biosimilars Conferencehttps://pharmaphorum.com/partner-content/10-key-reasons-to-attend-smis-10th-annual-biosimilars-conference/
Three Interactive Sessions to take place at the Respiratory Drug Delivery Conference Share XThree Interactive Sessions to take place at the Respiratory Drug Delivery Conferencehttps://pharmaphorum.com/partner-content/three-interactive-sessions-to-take-place-at-the-respiratory-drug-delivery-conference/
Exclusive interview with AstraZeneca ahead of upcoming Wearable Injectors & Connected Devices Share XExclusive interview with AstraZeneca ahead of upcoming Wearable Injectors & Connected Deviceshttps://pharmaphorum.com/partner-content/exclusive-interview-with-astrazeneca-ahead-of-upcoming-wearable-injectors-connected-devices/
Speaker Interview with iVeena Released for 3rd Ophthalmic Drugs Conference Share XSpeaker Interview with iVeena Released for 3rd Ophthalmic Drugs Conferencehttps://pharmaphorum.com/partner-content/speaker-interview-with-iveena-released-for-3rd-ophthalmic-drugs-conference/
pharmaphorum welcomes George Underwood to its editorial helm Share Xpharmaphorum welcomes George Underwood to its editorial helmhttps://pharmaphorum.com/news/pharmaphorum-welcomes-george-underwood-to-its-editorial-helm/
STEM Healthcare appoints Jason McKenna as CEO Share XSTEM Healthcare appoints Jason McKenna as CEOhttps://pharmaphorum.com/partner-content/stem-healthcare-appoints-jason-mckenna-as-ceo/
